share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/08/19 15:19

Moomoo AI 已提取核心訊息

Core Scientific has completed its private offering of $460 million 3.00% Convertible Senior Notes due 2029, including the full exercise of the initial purchasers' $60 million option. The notes will accrue interest at 3.00% per annum, payable semi-annually, with maturity on September 1, 2029. The initial conversion rate is 90.9256 shares per $1,000 principal amount, representing a conversion price of approximately $11.00 per share.The company will use approximately $61.2 million of the net proceeds to repay outstanding loans under its credit agreement and $150 million to redeem all outstanding 12.50% Secured Notes due 2028. The remaining proceeds will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.The notes include provisions for early conversion under specific circumstances and redemption options after September 7, 2027, subject to certain conditions. Core Scientific can settle conversions through cash, common stock, or a combination thereof at its discretion. The notes were offered to qualified institutional buyers under Rule 144A of the Securities Act.
Core Scientific has completed its private offering of $460 million 3.00% Convertible Senior Notes due 2029, including the full exercise of the initial purchasers' $60 million option. The notes will accrue interest at 3.00% per annum, payable semi-annually, with maturity on September 1, 2029. The initial conversion rate is 90.9256 shares per $1,000 principal amount, representing a conversion price of approximately $11.00 per share.The company will use approximately $61.2 million of the net proceeds to repay outstanding loans under its credit agreement and $150 million to redeem all outstanding 12.50% Secured Notes due 2028. The remaining proceeds will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.The notes include provisions for early conversion under specific circumstances and redemption options after September 7, 2027, subject to certain conditions. Core Scientific can settle conversions through cash, common stock, or a combination thereof at its discretion. The notes were offered to qualified institutional buyers under Rule 144A of the Securities Act.
Core Scientific已經完成了46000萬美元的3.00%可轉換高級票據的私募發行，包含初始購買者6000萬美元期權的完整行使。該票據將按每年3.00%的利率計息，按半年支付，到期日爲2029年9月1日。初始轉換比率爲每1000美元票面金額90.9256股，相當於每股大約11.00美元的轉換價格。公司將使用約6120萬美元的淨收益償還其信貸協議下的未償貸款，15000萬美元用於贖回所有到期2028年的12.50%擔保票據。剩餘收益將用於一般企業用途，包括運營資金、營業費用、資本支出及潛在收購。該票據包含在特定情況下提前轉換的條款，且在2027年9月7日後有贖回選項，受某些條件的限制。Core Scientific可以按其自行決定通過現金、普通股票或兩者組合來結算轉換。該票據根據《證券法》第144A條款向合格機構買家提供。
Core Scientific已經完成了46000萬美元的3.00%可轉換高級票據的私募發行，包含初始購買者6000萬美元期權的完整行使。該票據將按每年3.00%的利率計息，按半年支付，到期日爲2029年9月1日。初始轉換比率爲每1000美元票面金額90.9256股，相當於每股大約11.00美元的轉換價格。公司將使用約6120萬美元的淨收益償還其信貸協議下的未償貸款，15000萬美元用於贖回所有到期2028年的12.50%擔保票據。剩餘收益將用於一般企業用途，包括運營資金、營業費用、資本支出及潛在收購。該票據包含在特定情況下提前轉換的條款，且在2027年9月7日後有贖回選項，受某些條件的限制。Core Scientific可以按其自行決定通過現金、普通股票或兩者組合來結算轉換。該票據根據《證券法》第144A條款向合格機構買家提供。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    MicroAlgo
    MLGO
    -- 13.990
    Bakkt Holdings
    BKKT
    -- 13.830
    Rekor Systems
    REKR
    -- 1.150
    Aeva Technologies
    AEVA
    -- 4.740
    Airship AI
    AISP
    -- 4.530
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點